Cytek Biosciences (NASDAQ:CTKB) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. The company reported quarterly sales of $51.500 million which beat the analyst consensus estimate of $50.696 million by 1.59 percent. This is a 7.29 percent increase over sales of $48.000 million the same period last year.